Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZUR-4: Neoadjuvant Dostarlimab Plus CAPEOX in Colon Cancer
NCT06567782Phase 2Recruiting
- Sponsor
- GSK
- Start
- Feb 2025
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 6
01
Overview
A Phase 2 trial of dostarlimab in colon cancer, sponsored by GSK. Started Feb 2025; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06567782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567782.